Advance in the clinical diagnosis and treatment of Alzheimer's disease
LIAO Jiang-feng
CHEN Xiao-chun
Abstract：The paradigm for diagnosing and treating Alzheimer's disease(AD)is undergoing a profound transformation,moving towards a biomarker-driven and early-intervention-oriented stage.In diagnosis,the emergence of high-performance biomarkers such as plasma p-tau217 has significantly advanced the ultra-early detection of AD pathology,substantially shifting the diagnostic window forward.Meanwhile,multimodal molecular imaging techniques based on the ATN(VIS)biomarkers diagnosis framework,including amyloid β-protein(Aβ)-PET and tau-PET,enable in vivo visualization and typing of pathological burden,greatly enhancing diagnostic accuracy.The therapeutic field has also witnessed significant progress,with anti-Aβ monoclonal antibody drugs like Lecanemab and Donanemab receiving approval,demonstrating that disease-modifying therapy(DMT)targeting core pathology can effectively delay clinical decline.Current research has expanded to multiple pathological mechanisms,such as Aβ,tau and neuroinflammation,alongside active exploration of personalized combination therapy strategies.Future challenges lie in promoting the clinical translation and equitable application of these innovations to address the growing public health burden.This article systematically reviews the latest advancements in the field of biomarkers diagnosis and targeted therapy for AD,aiming to provide important references for establishing an early and precise diagnosis and treatment system and promoting clinical translation applications.
Keywords：Alzheimer diseaseBiomarkersDisease-modifying therapy(not in MeSH)Precision medicineReview
Publication Date：2026-02-25
Online Publishing Date：2026-04-07(First online date of this platform, not the publication date of the document)
Pages：9( 179-187 )